ProfessorEd Tate, FRSC FRSB
GSK Chair in Chemical Biology
Department of Chemistry - Faculty of Natural Sciences
Orcid identifier0000-0003-2213-5814 (opens in a new tab)
- GSK Chair in Chemical BiologyDepartment of Chemistry - Faculty of Natural Sciences
- 020 7594 3752 (Work)
- 301B, Molecular Sciences Research Hub, White City Campus, United Kingdom
- The Francis Crick Institute, 1 Midland Rd, London, NW1 1AT, UK
RESEARCH
Please visit the Tate group website for more information.
GRANTS
- STANDARD - RESPONSEAn Accumulation Rulebook & Vulnerability Atlas for Klebsiella spp.Wellcome Trust22 Mar 2026 - 21 Mar 2029
- STANDARD - CALLTargeting Hedgehog Acyltransferase in vivo for treatment of cancer and fibrotic diseasesMedical Research Council (MRC)1 Feb 2026 - 31 Jan 2027
- STANDARD - CALLGSK-Fleming Initiative, Grand Challenge 2Glaxosmithkline Research and Development Ltd11 Nov 2025 - 10 Nov 2028
- STANDARD - CALLGSK-Fleming Initiative Grand Challenge 3 Antifungal Drug DiscoveryGlaxosmithkline Research and Development Ltd5 Nov 2025 - 4 Nov 2028
- STANDARD - CALLAntibody Drug Conjugates targeting N-myristoyltransferaseMyricx Pharma Limited6 Oct 2025 - 5 Oct 2029
- STANDARD - CALLAn integrated analysis of S-acylation dynamics and its importance in cell physiologyBiotechnology and Biological Sciences Research Council1 Jul 2025 - 30 Jun 2030
- STANDARD - CALLNext-generation tumour associated protease sensitive antibody drug conjugate linkers for breast and colorectal cancerCancer Research UK1 Jul 2025 - 31 Jul 2027
- STANDARD - CALLResearch Cluster in Health Sciences, with the University of Hong Kong - Phase 2 LSCCB InnoHKHKCHE1 May 2025 - 30 Apr 2030
- STANDARD - CALLDirect-from-tumour discovery of next generation antibody-drug conjugate (ADC) linkersEngineering & Physical Sciences Research Council1 Jan 2025 - 31 Dec 2027
- STANDARD - CALLUnlocking novel payload release mechanisms for antibody drug conjugates (ADCs)Cancer Research UK1 Sep 2024 - 31 Aug 2025
- STANDARD - CALLHuman functional genomics of post-translationally modifying clinical coding variantsMedical Research Council (MRC)14 May 2024 - 13 May 2028
- STANDARD - CALLPlasmepsin inhibitors as antimalarialsMedical Research Council (MRC)1 Feb 2024 - 31 Oct 2026
- STANDARD - CALLUncovering the essential role of host hetero-hexameric ATPases in rhinovirus replicationMedical Research Council (MRC)2 Oct 2023 - 31 Mar 2027
- STANDARD - CALLDeveloping a rule book for rational discovery of molecular glues for intractable targets.Engineering & Physical Science Research Council (E1 Jul 2023 - 30 Jun 2028
- STANDARD - CALLShining light on dynamic post-translational modifications of RAS in cancerNetherlands Organisation for Scientific Research1 Jun 2023 - 31 May 2025
- STANDARD - CALLA novel and universal plug-and-play technology for molecular glue discoveryMedical Research Council (MRC)1 Apr 2023 - 30 Sep 2024
- STANDARD - CALLBRC Renewal - Infection & AMR themeImperial College Healthcare NHS Trust- BRC Funding1 Dec 2022 - 31 Mar 2028
- STANDARD - CALLDrugging the prostate cancer associated target GALNT7Prostate Cancer UK1 Nov 2022 - 30 Apr 2027
- GRANTPhotoactivatable molecular probes to study RNA-protein interactions - ICB CDT Co Funded studentshipVertex Pharmaceuticals (Europe) Ltd1 Oct 2022 - 30 Sep 2026
- STANDARD - CALLMRC UKRI IAA 22-25Medical Research Council (MRC)1 Apr 2022 - 31 Mar 2027
- GRANTProtein lipidation in cancer: discovery, mechanisms and target validationCancer Research UK1 Apr 2022 - 31 Mar 2027
- GRANTEd TateWorldwide Cancer Research1 Mar 2022 - 30 Jun 2025
- GRANTIdentifying novel determinants of Niraparib/Zejula PARP inhibitor response via integration of metabolomics and chemical proteomicsGlaxoSmithKline28 Feb 2022 - 27 Aug 2024
- GRANTCaught in the act: precision tools to unravel and diagnose glycoprotein misfolding- ICB CDT Co Funded studentshipVertex Pharmaceuticals (Europe) Ltd1 Oct 2021 - 30 Sep 2025
- GRANTBacterial DNA Repair as a Novel Therapeutic Target 2021Rosetrees Trust3 May 2021 - 2 May 2023